NCT00663650

Brief Summary

This study is an equivalency study designed as a randomized clinical trial. Patients with a biopsy proven nodular periocular basal cell carcinoma (BCC) who have agreed to have surgical excision will be eligible. Study patients will undergo surgical excision of the lesion and then be randomized to having frozen section or permanent section pathological control. For those patients randomized to permanent section control the sample will be sent to pathology and surgical reconstruction will be performed. Patients randomized to frozen section will have additional margins re-excised before reconstruction depending on the pathologic results. Tumor clearance rates after surgical excision will be compared between the two techniques as a primary study question. Patients will be followed long-term to determine recurrence rates in the two groups. The study is designed to determine if the two techniques are equivalent within a given margin of error with respect to outcome measures.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
290

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Aug 2008

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 22, 2008

Completed
3 months until next milestone

Study Start

First participant enrolled

August 1, 2008

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

July 12, 2011

Status Verified

July 1, 2011

Enrollment Period

4.3 years

First QC Date

April 18, 2008

Last Update Submit

July 11, 2011

Conditions

Keywords

Basal Cell CarcinomaBCCPeriocular BCCFrozen Section ControlPermanent Section ControlRecurrence Rates

Outcome Measures

Primary Outcomes (1)

  • The proportion of BCC's that are pathologically clear of tumor cells in the permanent section group compared with the frozen section group (presumably clear for all patients).

    1.5 years

Secondary Outcomes (1)

  • Clinical recurrence at 3 years

    4.5 years

Study Arms (2)

1

ACTIVE COMPARATOR

Permanent Section Control

Procedure: Permanent Section Control

2

ACTIVE COMPARATOR

Frozen Section Control

Procedure: Frozen Section Control

Interventions

After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised

1

After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old or greater
  • Diagnosed with clinically nodular BCC in the periocular region confirmed by tissue biopsy
  • Agreeable and medically able to undergo surgical excision of the BCC
  • Able to give informed consent and consent has been signed
  • Able to return for all follow up visits

You may not qualify if:

  • BCC greater than 2cm in diameter (based on clinical examination)
  • Patient with a medical condition predisposing to multiple BCC's (ex. basal cell nevus syndrome)
  • Recurrent BCC's (i.e. a BCC that has been treated previously by surgical or other modality and has recurred will not be eligible)
  • Clinically aggressive morpheaform subtype of BCC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hotel Dieu Hospital

Kingston, Ontario, K7L 5G2, Canada

RECRUITING

MeSH Terms

Conditions

Carcinoma, Basal Cell

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Basal Cell

Study Officials

  • Vladimir Kratky, MD, FRCSC

    Department of Ophthalmology, Queen's University, Kingston, ON

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Vladimir Kratky, MD, FRCSC

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 18, 2008

First Posted

April 22, 2008

Study Start

August 1, 2008

Primary Completion

December 1, 2012

Study Completion

June 1, 2013

Last Updated

July 12, 2011

Record last verified: 2011-07

Locations